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Aim To determine the prevalence, number, and location 
of multiple (≥2) T2-hyperintensities on brain magnetic res-
onance imaging (MRI) in children with neurofibromatosis 
type 1 (NF1) and their correlation with age, and to establish 
their sensitivity, specificity, and accuracy for the diagnosis 
of NF1 in children, especially in the early age (2-7 years).
Methods We performed a cross-sectional study of 162 pa-
tients with NF1 from Croatian Neurofibromatosis Associa-
tion Database and 163 control children between the ages 
of 2 and 18 years who underwent brain MRI between 1989 
and 2009.
Results Multiple T2-hyperintensities were present in 74% 
of NF1 patients and 1.8% of controls. They were mainly lo-
cated in the basal ganglia, brainstem, and cerebellum and 
were significantly decreased in prevalence and number in 
the older age. T2-hyperintensities had excellent diagnostic 
accuracy with the area under the receiver operating char-
acteristic (ROC) curve of 0.849 and 95% confidence inter-
val (CI) of 0.805-0.886. The diagnostic sensitivity, specific-
ity, and accuracy rate of T2-hyperintensities for NF1 were 
highest in the youngest age (2-7 years): 81% (95% CI 71%-
89.1%), 99% (95% CI 92.3%-100%), and 85.8 (95% CI 83.3-
93.8), respectively.
Conclusion This study strongly suggests the inclusion of 
T2-hyperintensities on brain MRI on the list of diagnostic 
criteria for NF1, especially in children of early age, when 
the clinical penetration of the NF1 gene has not yet been 
completely finished.
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Neurofibromatosis type 1 (NF1) or von Recklinghausen’s 
disease is one of the most common autosomal dominant 
inherited diseases in humans with an estimated birth inci-
dence of 1/2500 and a disease prevalence of 1/3000-4000 
(1). NF1 gene is located on the pericentromeric region of 
chromosome 17q11.2 (2). It is a megagene, spaning 350 
kb of genomic DNA and consisting of 60 exons encoding 
an 11-13 kb GTPase activating protein – neurofibromin of 
2818 amino acids (3,4). The mutation rate for NF1 gene is 
high. A half of all NF1 cases are familial, while the other half 
is caused by a new mutation (5). Genetic molecular test-
ing confirms the disease’s existence but has no predictive 
value for its severity and course.
In the past thirty years, the diagnosis of NF1 was made us-
ing a set of clinical criteria developed by the National In-
stitutes of Health Consensus Conference, so called NIH di-
agnostic criteria (6). The diagnosis of NF1 is based on the 
presence of two or more of the following: 1) six or more 
café au lait macules, the greatest diameter of which is more 
than 0.5 cm in prepubertal patients and more than 1.5 cm in 
postpubertal patients; 2) two or more neurofibromas of any 
type, or one plexiform neurofibroma; 3) freckling in the axil-
lary or inguinal region; 4) optic glioma; 5) two or more Lisch 
nodules; 6) a distinctive osseous lesion such as sphenoid 
dysplasia or pseudarthrosis; 7) a first-degree relative with 
NF1 according to the preceding criteria. However, the diag-
nosis cannot always be made in all children using the above 
mentioned criteria, especially in early childhood when the 
penetration of NF1 gene in usually not complete (7,8).
The cranial magnetic resonance imaging (MRI) is the best 
method for showing many features of NF1, including optic 
pathway gliomas, brain tumors of various locations, brain 
stem  tumors,  and  orbital  neurofibromas.  Most  frequent 
brain changes in children with NF1 are areas of increased 
T2-weighted signal intensity – T2-hyperintensities or “un-
identified bright objects,” as they usually cannot be visu-
alized using T1-weighted imaging. T2-hyperintensities are 
age-related findings on MRI and have been observed in 
43%-93% of children who suffer from NF1 (9-11). These le-
sions do not exert mass effect, contrast enhancement, or 
surrounding edema. They are most commonly found in 
the  basal  ganglia,  thalamus,  cerebellum,  and  brainstem 
(12). Former research on multiple T2-hyperintensities on 
brain MRI in children as diagnostic criterion for NF1 was 
contradictory and scarce (13-17).
The aim of this cross-sectional study was to determine the 
prevalence, number, and location of multiple (≥2) brain T2-
hyperintensities on MRI, and their correlation with age in 
children with NF1. A further aim was to determine the indi-
cators of diagnostic accuracy of T2-hyperintensities in chil-
dren of different ages, especially in the early age (from 2 to 
7 years) when the NF1 gene penetration is still not com-
pleted.
PatientS anD MethODS
Study design, setting, data collection, and patients
This cross-sectional study with prospective data collection 
was performed at Sabol Outpatient Clinic for Sick Children 
in Zagreb, Croatia, from March to November 2010. It was 
approved by the Ethics Committee of Zagreb University 
School of Medicine.
The study included 325 patients of both sexes between 2 
and 18 years old, divided into two groups. The NF1 patient 
group consisted of 162 children who were diagnosed with 
NF1 by the NIH diagnostic criteria (6) and underwent crani-
al MRI examinations. They were selected from the Croatian 
Neurofibromatosis Association Database, created by the 
main investigator on the basis of routine clinical follow-
up of NF1 patients between January 1989 and December 
2009 at the Department of Pediatrics, University Hospi-
tal Zagreb, Clinical Medical Center, and Sabol Outpatient 
Clinic for Sick Children in Zagreb. For each patient, data 
were available about NIH diagnostic criteria, presence or 
absence of T2-hyperintensities on cranial MRI examination, 
their number and location, as well as data on other chang-
es and complications of the disease. Although some of the 
patients had more than one MRI scanning, cross-sectional 
analysis included only the data about clinical NIH diagnos-
tic manifestations of NF1 and MRI changes at the time of 
the first MRI.
The control group included 163 patients selected by ac-
cidental  sampling  from  patient  database  of  the  above 
mentioned institutions (3542 patients) during the same 
period as the patient group who performed the brain MRI 
examination for other complaints not related to NF1. The 
exclusion criteria for control group were diseases in which 
T2-hyperintensities were expected: hypoxic-ischemic en-
cephalopathy, intracranial hemorrhage, infection, changes 
caused by radio- and/or chemotherapy, neurometabol-
ic diseases, brain heredodegenerative diseases, tumors, 
multiple sclerosis, and acute disseminated encephalo-
myelitis. NF1 and other neurocutaneous diseases were 
excluded by careful clinical examination. All patients CLINICAL SCIENCE 490 Croat Med J. 2011; 52: 488-96
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of both groups were clinically examined and prospectively 
evaluated by the head investigator.
Brain MRi
The  examinations  of  participants  of  both  groups  were 
done with the MRI scanners operated at different magnet-
ic field strength in different medical institutions in Croa-
tia. The brain MR images were performed with a low- and 
medium-field systems (0.2-1.0 Tesla) on 90 children from 
NF1 patient group and 79 children from the control group, 
and with high-field MRI systems (1.5 -3 Tesla) on 72 chil-
dren from the NF1 patient group and 84 children from the 
control group. Standard spin-echo T1- and T2-weighted 
sequences  in  the  axial  and  sagittal  planes,  respectively, 
and axial fluid-attenuated inversion recovery T1- and T2-
weighted sequences were obtained in all patients. Addi-
tional T1- or T2-weighted coronal images were obtained 
in most patients. A contrast agent (gadopentetate dime-
glumine) was administered at 0.1 mmol/kg to 91 of 162 
(56.2%) children from NF1 group and to 2 of 163 (1.2%) 
children from the control group. No adverse events were 
noticed in either of the groups.
All MR scans were examined independently by two neuro-
radiologists, who used visual inspection and were blinded 
for each group of patients. T2-hyperintensities on MRI were 
defined operationally as areas of confluent hyperintensity 
(signal intensity higher than that of cortical gray matter) 
on the proton density and the T2-weighted images with-
out associated mass effect. A specific attention was paid 
to the number of lesions, location, signal characteristics on 
T1- and T2-weighted images, and presence or absence of 
contrast enhancement. In case of incompatible findings, 
the consensus between two neurologists was made.
Reference standard
The basic reference standard – NIH diagnostic criteria for 
NF1 (6) were used to determine or exclude a definitive 
clinical diagnosis of NF1. Presence of at least two of seven 
NIH diagnostic criteria confirmed clinical diagnosis of NF1 
in children.
Statistical analysis
For continuous variables, such as the number of T2-hy-
perintensities or age at presentation, the differences be-
tween groups were compared using t test. Categorical 
variables such as sex, type of NF1 (sporadic or famil-
ial), and brain location of T2-hyperintensities were estimat-
ed in terms of relative frequencies. For these variables, the 
comparison between two groups was made using contin-
gency tables and χ2 test. For the analysis of correlation of 
number of T2-hyperintensities and the age of patients, the 
Pearson test of correlation was performed. For the analy-
sis of association of prevalence of T2-hyperintensities and 
the age of patients, children were grouped according to 
age. For presence/absence of T2-hyperintensities on brain 
MRI, we constructed a 2 × 2 contingency table that con-
sisted of true-positive, true-negative, false-positive, false-
negative, and true-negative results in accordance with the 
reference standard used in each case. The sensitivity and 
specificity of T2-hyperintensities as diagnostic criterion for 
NF1, as well as the negative and positive predictive value, 
odds ratio (OR), and accuracy rate were calculated by using 
standard formula. Indicators of diagnostic accuracy were 
evaluated in different age groups: 2-7 years, 8-12 years, and 
13-18 years. The accuracy of T2-hyperintensities in diagno-
sis of NF1 in children was verified by receiver operating 
characteristic (ROC) curve. P value <0.05 was indicated as 
significant difference.
ReSultS
the clinical and epidemiological characteristics of 
patients and controls
The patient and control group were comparable according 
to age and sex. The median age of 162 children in the NF1 
patient group (91 boys and 71 girls) at the time when the 
definite clinical diagnosis of NF1 was made was 5.6 years 
(range 0.3-17.9). The median age of children with NF1 and 
of 163 control group children (82 boys and 81 girls) at the 
time when brain MRI examinations were made was 7.7 years 
(range 1.9-18.3) and 8.2 years (range 2.0-17.9), respectively 
(P = 0.196). Of the children with NF1, 87 (53.7%) were familial 
and 73 (45.1%) were sporadic cases. For two adopted chil-
dren (1.2%), family history was unknown. Ten NF1 patients, 
all sporadic cases with multiple café au lait spots as the only 
diagnostic sign of NF1, underwent brain MRI examination 
prior to meeting the NIH diagnostic criteria. At the age of 
13, they all met the NIH diagnostic criteria for NF1.
Prevalence and location of t2-hyperintensities on brain 
MRi
Multiple (≥2) T2-hyperintensities on brain MRI were found in 
119 of 162 children with NF1 (73.5%) and only 7 of 163 chil-
dren in the control group (4.3%) (P < 0.001). Four children in 491 Sabol et al: T2-hyperintensities on brain MRI in NF 1
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the control group had a single lesion and other 3 had two or 
more lesions. The actual prevalence of multiple T2-hyperin-
tensities in the control group was 1.8% (3/163 patients).
In the NF1 group, there were 636 T2-hyperintesities (medi-
an 3, range 0-16) and in the control group there were only 
11 (median 0, range 0-3) (P < 0.001). T2-hyperintensities in 
the patient group were mainly located in the basal gan-
glia (81%), most frequently in the globus pallidus (78%), 
brainstem (38%), and cerebellum (36%) (Figure 1A and 1B). 
In the control group, they were located in the subcortical 
structures of the cerebrum (3/7 patients) and parasagit-
tal watershed regions (3/7 patients). Only one patient in 
the control group had two T2-hyperintensities in the bas-
al ganglia (putamen) (Table 1). The overall agreement in 
identification of multiple (≥2) T2-hyperintensities between 
the two radiologists was 99.4%. The agreement for local-
ization and total number of lesions was 91.4% and 77%, 
respectively.
There were no significant differences between the groups 
of patients who were examined with low-, medium-, and 
high-field MRI systems in the prevalence (72% and 75%, 
P = 0.363) and the number of T2-hyperintensities (median 4, 
range 1-16 and median 5, range 1-14, P = 0.076). Also, there 
were no significant differences in locations of T2-hyperin-
tensities between two groups: the basal ganglia (P = 0.160), 
brainstem (P = 0.554), and cerebellum (P  = 0.738) (Table 2).
the association of t2-hyperintensities and age
There was a significant decrease in the frequency of T2-
hyperintensities with age, from 82% at 2-4 years and 79% 
at 5-7 years to 22% at 16-18 years (P = 0.002) (Figure 2). The 
T2-hyperintensities presence/absence ratio until the end 
of puberty (age 15) was in favor of the presence. However, 
in adolescence the presence of T2 hyperintensities signifi-
cantly decreased and the ratio was in favor of the absence 
(Figure 2). There was a significant decrease in number of 
lesions from the earliest age, 2-7 years (total number 368, 
median 6, range 0-16) until puberty/adolescence, 13-18 
years (total number 40, median 3, range 0-8, P = 0.011) 
(Figure 3).
Clinical diagnostic sensitivity and specificity of presence 
of t2-hyperintensivities on brain MRi
Clinical diagnostic sensitivity and specificity of the pres-
ence of T2-hyperintensities in the group of children with 
NF1 aged 2-18 years was 74% (95% CI 66%-80.1%) and 98% 
(95% CI 94.7%-99.6%), respectively, with positive predictive 
value, negative predictive value, and accuracy rate of 98% 
(95% CI 93%-99.5%), 79% (95% CI 72.6%-84.2%), and 86% 
(95% CI 82%-89.5%), respectively. Positive likelihood ratio, 
negative likelihood ratio, and odds ratio were 40 (95% CI 
13-123), 3.7 (95% CI 2.9-4,8), and 1.5 (95% CI 0.4-4.9), re-
spectively.
Figure 1.
Multiple hyperintensities on t2-weighted cranial magnetic resonance imaging in children with neurofibromatosis type 1. axial image shows multiple 
oval discrete lesions with increased intensity (arrows) in the globus pallidus (A); axial fluid attenuated inversion recovery image shows multiple diffuse 
t2-hyperintensities (arrows) in the cerebellum (B)CLINICAL SCIENCE 492 Croat Med J. 2011; 52: 488-96
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Sensitivity of T2-hyperintensities (81%, 95% CI 71%-89.1%), 
positive predictive value (99%, 95% CI 91.8%-99.9%), nega-
tive predictive value (82%, 95% CI 72.3%-89.7%), positive 
likelihood ratio (56.9, 95% CI 8-399), negative likelihood ra-
tio (5.3, 95% CI 3-8), odds ratio (3, 95% CI 0.4-23.3), and the 
accuracy rate (89%) were highest in the youngest patient 
group, 2-7 years, and decreased as patients got older. In 
the age groups 8-12 years and 13-18 years, sensitivity of T2-
hyperintensities was 76% (95% CI 62%-86%) and 48% (CI 
30%-68%),  respectively.  Specificity  of T2-hyperintensities 
was high in all age groups, ranging from 97% (95% CI 88%-
100%) to 100% (Figure 4).
ROC analysis
ROC analysis for the evaluation of diagnostic accuracy in 
the total group of children (N = 325) showed that multiple 
T2-hyperintensities  on  brain  MRI  can  have  excellent  di-
agnostic accuracy, with the area under the ROC curve of 
0.849 (95% CI 0.805-0.886; P < 0.001) (Figure 5).
DiSCuSSiOn
Our study showed very high specificity of the presence of 
T2-hyperintensities on brain MRI in diagnosis of NF1 in chil-
dren – 98% (from 97% to 100% depending on age). The 
sensitivity was also high – 74% for all age groups, but was 
the highest in children of early age, until 7 years – 81%. 
None of the previous studies examined the indicators of 
diagnostic accuracy of T2-hyperintensities, particularly in 
the early age. ROC analysis showed an excellent diagnos-
tic accuracy of T2-hyperintensities on brain MRI in children 
and suggested their clinical usefulness as a diagnostic cri-
terion for NF1, especially in the early age when the defini-
tive clinical diagnosis cannot be established using the NIH 
diagnostic criteria in all patients. T2-hyperintensities can be 
taBle 1. Prevalence, total number, and locations of t2-hyperintensities on brain magnetic resonance imaging in children with neu-
rofibromatosis type 1 (nF1) (n = 162) and children without nF1 (n = 163)
Children t2-hyperintensities in children
with nF1 without nF1 with nF1 without nF1
t2-hyperintensities no. % no % no. median (range) no. median (range)
Prevalence 119/162* 73.5 7/163*   4.3 636† 3 (0-16) 11† 0 (0-3)
location of lesions
basal ganglia:   96/119 80.7 1/7 14.3 1 (0-9) 0 (0-2)
globus pallidus   93/119 78.2 1 (0-7)
nucleus caudatus   19/119 16.0 0 (0-3)
putamen   17/119 14.3 1/7 14.4 0 (0-3) 0 (0-2)
brainstem   45/119 37.8 0 (0-6)
cerebellum   43/119 36.1 0 (0-7)
cerebrum   31/119 26.0 3/7 42.9 0 (0-5) 0 (0-1)
šeriventricular  0  0 3/7 42.9 – 0 (0-3)
*P < 0.001 vs prevalence of t2-hyperintensities in children with nF1 and children without nF1 (t test).
†P < 0.001 vs total number of t2-hyperintensities in children with nF1 and children without nF1(t test).
taBle 2. Prevalence, total number, and locations of t2-hyperintensities on brain magnetic resonance imaging (MRi) in children with 
neurofibromatosis type 1 (nF1) assessed by low- and medium field MRi (n = 90) and high-field MRi (n = 72).
no. (%) of children 
with nF1 assessed by
Median (range) of the number of 
t2-hyperintensities in children with nF1 assessed by
t2-hyperintensities
low- and 
medium-field MRi
high-field 
MRi
low- and 
medium-field MRi
high-field 
MRi P
Prevalence   65 (72.2)   54 (75.0) 0.363*
total number of lesions 322 314 4 (1-16) 5 (1-14) 0.076*
location of lesions:
basal ganglia   51 (56.7)   45 (62.5) 2 (0-9) 2 (0-8) 0.160†
brainstem   27 (30.0)   18 (25.0) 0 (0-6) 0 (0-4) 0.554†
cerebellum   19 (21.1)   24 (33.3) 0 (0-7) 0 (0-6) 0.738†
*t test.
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used to establish the definitive clinical diagnosis of NF1 as 
a second, crucial criterion, as it was shown in our 10 pa-
tients with the sporadic form of the disease. The finding 
of multiple T2-hyperintensities in the basal ganglia, brain 
stem, and cerebellum should raise the suspicion to NF1 
and necessitate clinical search for other NF1 features of di-
agnostic value.
The diagnostic specificity and sensitivity of T2-hyperinten-
sities were examined in only two studies so far (15,17), with 
results similar to ours. The retrospective study by DeBella 
et al (15) reported the specificity of T2-hyperintensities of 
84%  and  74%,  respectively,  assessed  independently  by 
two neuroradiologists in 19 affected children and 19 age-
matched controls, aged 4-10. The sensitivity of T2-hyper-
intensities in the same study was 95% and 100%, respec-
tively. The prospective study by Lopes Ferraz Filho et al (17) 
showed the specificity of 100% and the sensitivity of 70% 
Figure 2.
Prevalence of t2-hyperintensities on brain magnetic resonance imaging 
(MRi) in different age groups of children with neurofibromatosis type 1. 
the frequency of t2-hyperintensities significantly decreased from age 
2-4 years to age 16-18 years (χ2 = 12.03, P = 0.002). Open bars – t2-hyper-
intensities present; closed bars – t2-hyperintensities absent.
Figure 3.
the correlation of the number of t2-hyperintensities and age in 119 chil-
dren with neurofibromatosis type 1. Pearson correlation showed a sig-
nificant correlation between the number t2-hyperintensities and age of 
patients with nF1 (r2 linear = 0.100, P = 0.011).
Figure 4.
Clinical diagnostic sensitivity, specificity, and positive and negative pre-
dictive value of t2-hyperintensities in patients with neurofibromatosis 
type 1 of different age. Closed bars – sensitivity; open bars – specific-
ity; light gray – positive predictive value; dark gray – negative predic-
tive value.
Figure 5.
Receiver operating characteristic (ROC) curve of t2-hyperintensities on 
brain magnetic resonance imaging. ROC curve (full line) and confidence 
interval (dashed line) for t2-hyperintensities. Gray line defines the area 
of 0.5.CLINICAL SCIENCE 494 Croat Med J. 2011; 52: 488-96
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in 40 children with NF1 and 48 children from the control 
group aged 2-18.
The data collection in this study reflects our routine clinical 
practice. We also recommend routine application of brain 
MRI in patients with NF1 in the basic clinical evaluation of 
the severity of disease because of numerous and, some-
times, severe organic and functional changes of central 
and peripheral nervous system in NF1 (7).
Application of MRI should not be limited only to symptom-
atic cases with NF1 as it has been recommended so far by 
some authors (14). We recommend the evaluation by brain 
MRI in children with NF1 during early childhood, after the 
second year, before the eighth year, or at the time of es-
tablishing the definitive clinical diagnosis if it is established 
after the previously mentioned age. Brain MRI can confirm 
the presence of T2-hyperintensities that, apart from their 
diagnostic value, can contribute to NF1 cognitive impair-
ments through thalamo-cortical dysfunction (18). The re-
cent studies have suggested that T2-hyperintesities may 
represent pathological foci of hyperplastic or dysplastic gli-
al proliferation with vacuolar or spongiotic changes, with 
fluid-filled, coalescted, or conflated vacuoles (19). MRI re-
veals also other specific changes as optic glioma and other 
brain tumors, which develop in NF1 patients with higher 
frequency than in general population (20). Other NIH diag-
nostic changes, as sphenoid dysplasia, also demand neu-
roradiologic  evaluation.  Early  detection  of  optic  glioma 
and other neoplasms by MRI in NF1, which can be asymp-
tomatic for longer period, can assure systematic and care-
ful prospective ophthalmologic and neurologic follow-up 
and prompt intervention in the case of the appearance of 
symptoms.
The results of our study showed that the MRI systems of 
different field strength had no significant influence on the 
detection of brain T2-hyperintensities. Namely, the differ-
ences in prevalence, total number of the brain lesions, and 
their frequency in various brain regions were not signifi-
cant between the group of patients examined with low/
medium-field systems and those examined with high-field 
systems.
The total prevalence of multiple (≥2) T2-hyperintensities of 
74% on the brain MRI in children with NF1 in our study 
is concordant to the majority of previous studies done in 
patients of the same age – from 50% to 93% (13,17,21-
27). In our control group, only several patients (4.3%) 
had T2-hyperintensities and only 3 patients (1.8%) 
had multiple (≥2) lesions. Although the mode of sample 
selection for our control group cannot present the ideal re-
flection of healthy pediatric population, the prevalence of 
T2-hyperintensities in our study is the same to that of the 
accidental findings of T2-hyperintensities in healthy chil-
dren up until the age of 18 established by Kim and al (2.2%) 
(28). In other studies, the presence of T2-hyperintensities 
was determined in 8 out of 1000 (0.8%) healthy individuals, 
3-83 years old (29).
The multiple T2-hyperintensities in our patients were most 
frequently localized in the basal ganglia (predominantly in 
the globus pallidus), brainstem, or cerebellum. These re-
sults are concordant to the results of practically every for-
mer study (10-13,15-17,24). The locations of multiple T2-
hyperintensities in our NF1 patients were different from 
those in healthy individuals. The majority of lesions in the 
control group were distributed outside the above men-
tioned three regions, ie, in the cerebrum, which is concor-
dant to the findings of previous studies (15,29).
The agreement in identification of the number and loca-
tion of T2-hyperintensities between the two neuroradiol-
ogists was 77% and 91.4%, respectively. This inconsistency 
is caused by the subjectivity of visual interpretation and 
difficulty in defining the exact number of lesions locat-
ed in the two neighboring brain regions. Namely, T2-hy-
perintensities in NF1 can present themselves as discrete 
or diffuse lesions (10). Discrete lesions have well defined 
margins that are distinct from normal tissue, while diffuse 
lesions have poorly defined margins and confluent ap-
pearance.
In spite of the time limitation of the cross-sectional study 
design, a relatively large sample of respondents gives us 
a possibility to conclude that T2-hyperintensities on brain 
MRI in pediatric patients with NF1 tend to develop in tod-
dlerhood and at preschool age. This is earlier than most 
NIH  diagnostic  features,  with  the  exception  of  multiple 
café au lait spots. The latter feature is in the most cases the 
first suspected sign with predictive value in the diagnosis 
of NF1 (30).
This study found a significant association between T2- hy-
perintensities and age. Both the prevalence and the num-
ber of lesions decreased with age, concordant to the find-
ings of other researchers (10,12). Other prospective studies 
showed that most T2-hyperintensities on brain MRI com-
pletely disappeared during late childhood and seemed to 
be benign (21,24,31,32). On the other hand, cross-sectional 495 Sabol et al: T2-hyperintensities on brain MRI in NF 1
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study by Szudek and Friedman (16), designed similarly as 
ours, showed that the frequency of T2-hyperintensities did 
not change with age.
Our clinical experience and data from this study also show 
that the clinical diagnosis of NF1 cannot be made using 
the NIH diagnostic criteria in all children, especially in pa-
tients of early age and in sporadic cases. In today’s practice, 
there are still many cases of late clinical diagnosis, despite 
of clearly defined clinical diagnostic criteria for NF1 (6). 
About 50% of children and 33% of adults had been treated 
for complications associated with NF1 before the clinical 
diagnosis of the disease was established. Moreover, 35% 
of children at the age of 5 were not diagnosed. Parents of 
children suspected of having NF1 want to have the diag-
nosis confirmed as early as possible (33). A serious diagnos-
tic problem occurs in young children who already develop 
complications of the disease before showing any of the 
NIH diagnostic criteria (34). Ninety-seven percent of our 
patients were diagnosed by using a set of NIH diagnostic 
criteria until the age of 8, when the NF1 gene penetration 
should be complete. The remaining 3% were diagnosed 
later in life – until the age of 13. The results are similar to 
the results of previous investigations (8,9).
As far as 15 years ago, several authors (21-26) suggested, 
due to the impossibility to establish the timely diagnosis 
of NF1 using NIH diagnostic criteria in some children, es-
pecially in their early age, that T2-hyperintensities on the 
brain MRI were specific and characteristic sign of NF1 and 
can be an additional diagnostic criterion for the disease. 
However, the expert consensus did not support the use of 
T2- hyperintensities because data on their specificity were 
scarce (14). On the other hand, more recent research con-
firms the value of T2-hyperintensities as a diagnostic sign 
for NF1 in children (15,17).
In conclusion, our results of high prevalence, characteris-
tic location, and high specificity and sensitivity of T2-hy-
perintensities on brain MRI strongly suggest their inclusion 
as diagnostic criterion for NF1 in children. As a diagnostic 
sign, they show very high levels of accuracy, the highest 
until 8 years, when the clinical penetration of the NF1 gene 
is not yet finished.
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